Subject(s)
Cardiology/standards , Hemorrhage/therapy , Hemostasis , Venous Thromboembolism/blood , Venous Thromboembolism/therapy , Anticoagulants , Blood Coagulation , Elasticity , Fibrinogen/analysis , Hospitalization , Humans , Perioperative Care , Perioperative Period , Practice Guidelines as Topic , ViscositySubject(s)
Anemia , Consensus , Postpartum Period/blood , Pregnancy Complications, Hematologic , Adult , Anemia/blood , Anemia/therapy , Blood Component Transfusion , Female , Gynecology , Humans , Obstetrics , Practice Guidelines as Topic , Pregnancy , Pregnancy Complications, Hematologic/blood , Pregnancy Complications, Hematologic/therapyABSTRACT
Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral anticoagulants SUMMARY: One of the key benefits of the direct oral anticoagulants (DOACs) is that they do not require routine laboratory monitoring. Nevertheless, assessment of DOAC exposure and anticoagulant effects may become useful in various clinical scenarios. The five approved DOACs (apixaban, betrixaban, dabigatran etexilate, edoxaban and rivaroxaban) have different characteristics impacting assay selection and the interpretation of results. This article provides an updated overview on (i) which test to use (and their advantages and limitations), (ii) when to assay DOAC levels, (iii) how to interpret the results relating to bleeding risk, emergency situations and perioperative management, and (iv) what is the impact of DOACs on routine and specialized coagulation assays. Assays for anti-Xa or anti-IIa activity are the preferred methods when quantitative information is useful, although the situations in which to test for DOAC levels are still debated. Different reagent sensitivities and variabilities in laboratory calibrations impact assay results. International calibration standards for all specific tests for each DOAC are needed to reduce the inter-laboratory variability and allow inter-study comparisons. The impact of the DOACs on hemostasis testing may cause false-positive or false-negative results; however, these can be minimized by using specific assays and collecting blood samples at trough concentrations. Finally, prospective clinical trials are needed to validate the safety and efficacy of proposed laboratory thresholds in relation to clinical decisions. We offer recommendations on the tests to use for measuring DOACs and practical guidance on laboratory testing to help patient management and avoid diagnostic errors.
Subject(s)
Anticoagulants/administration & dosage , Blood Coagulation Tests , Blood Coagulation/drug effects , Drug Monitoring/methods , Administration, Oral , Anticoagulants/adverse effects , Antithrombins/administration & dosage , Factor Xa Inhibitors/administration & dosage , Hemorrhage/chemically induced , Humans , Predictive Value of Tests , Reproducibility of ResultsABSTRACT
BACKGROUND: Non-specific hemostatic agents, namely activated prothrombin complex concentrate (aPCC), PCC and recombinant activated factor (F) VII (rFVIIa), can be used, off-label, to reverse the effects of FXa inhibitors in the rare cases of severe hemorrhages, as no approved specific antidote is available. We have evaluated the ability of aPCC, PCC and rFVIIa to reverse apixaban. METHODS: Healthy volunteer whole blood was spiked with therapeutic or supra-therapeutic apixaban concentrations and two doses of aPCC, PCC or rFVIIa. Tests performed included a turbidimetry assay for fibrin polymerization kinetics analysis, scanning electron microscopy for fibrin network structure observation, thrombin generation assay (TGA), thromboelastometry, prothrombin time and activated partial thromboplastin time. RESULTS: aPCC generated a dense clot constituting thin and branched fibers similar to those of a control without apixaban, increased fibrin polymerization velocity and improved quantitative (endogenous thrombin potential and peak height) as well as latency (clotting and lag times) parameters. Adding PCC also improved the fibrin and increased quantitative parameters, but fibrin polymerization kinetics and latency parameters were not corrected. Finally, rFVIIa improved latency parameters but failed to restore the fibrin network structure, fibrin polymerization velocity and quantitative parameters. CONCLUSION: aPCC was more effective than PCC or rFVIIa in reversing in vitro the effects of apixaban. aPCC rapidly triggered the development of an apparently normal fibrin network and corrected latency and quantitative parameters, whereas PCC or rFVIIa had only a partial effect.
Subject(s)
Factor Xa Inhibitors/pharmacology , Factor Xa Inhibitors/toxicity , Hemorrhage/prevention & control , Hemostasis/drug effects , Hemostatics/pharmacology , Pyrazoles/toxicity , Pyridones/toxicity , Antidotes/pharmacology , Blood Coagulation/drug effects , Blood Coagulation Factors/pharmacology , Factor VIIa/pharmacology , Fibrin/metabolism , Fibrin/ultrastructure , Healthy Volunteers , Hemorrhage/blood , Hemorrhage/chemically induced , Humans , Kinetics , Microscopy, Electron, Scanning , Partial Thromboplastin Time , Polymerization , Prothrombin Time , Recombinant Proteins/pharmacology , Thrombelastography , Thrombin/metabolismSubject(s)
Anesthetics, Dissociative/therapeutic use , Ketamine/therapeutic use , Neoplasms/complications , Pain, Intractable/drug therapy , Anesthetics, Dissociative/administration & dosage , Anesthetics, Dissociative/adverse effects , Humans , Injections, Spinal , Ketamine/administration & dosage , Ketamine/adverse effects , Neuralgia/drug therapy , Pain, Intractable/etiology , Palliative CareABSTRACT
Rare inherited bleeding disorders include fibrinogen disorders, and deficiencies of factors II (prothrombin), V, VII, X, XI, XIII, and combined V+VIII, and combined vitamin K-dependent factors, with general population prevalence rates between 1/500,000 and 1/2,000,000. These inherited disorders, transmitted as autosomal recessive traits, are characterized by a heterogeneous clinical presentation (asymptomatic, mild, moderate or severe bleeding tendency); this variability is more important for deficiencies with factor levels ranging from 5 to 50%. Individual bleeding risk assessment before an invasive procedure or during peri-partum period remains difficult, although an essential step to decide whether a substitution with clotting factor is necessary or not. Because there is a poor correlation between factor activity levels and the severity of bleeding symptoms, factor correction before an invasive procedure should not be based on factor level only, but physicians must also take into account the patient phenotype as well as the haemorrhagic risk of the procedure.
Subject(s)
Blood Coagulation Disorders, Inherited/genetics , Coagulation Protein Disorders/genetics , Hemorrhage/etiology , Blood Coagulation Disorders, Inherited/drug therapy , Blood Coagulation Disorders, Inherited/epidemiology , Blood Coagulation Factors/adverse effects , Blood Coagulation Factors/analysis , Blood Coagulation Factors/genetics , Blood Coagulation Factors/therapeutic use , Coagulation Protein Disorders/drug therapy , Coagulation Protein Disorders/epidemiology , Disease Management , Emergencies , Female , Genes, Recessive , Hemorrhage/prevention & control , Humans , Male , Postoperative Hemorrhage/etiology , Postoperative Hemorrhage/prevention & control , Postpartum Hemorrhage/etiology , Postpartum Hemorrhage/prevention & control , Pregnancy , Prevalence , Risk Assessment , Symptom Assessment , Thrombosis/chemically inducedABSTRACT
UNLABELLED: The study objective was to evaluate the potential increase in fatal bleeding risk related to curative anticoagulation of asymptomatic deep venous thromboses diagnosed by routine ultrasound screening after total hip/knee replacement or hip fracture using data from a comprehensive literature review. MATERIALS AND METHODS: Rates of venous thromboembolic and bleeding events occurring with recommended prophylaxis, and rates of iatrogenic bleeding risk induced by curative anticoagulation were extracted from randomized clinical trials, diagnosis codes at discharge, electronic databases, and observational studies. The fatal events rate was calculated for pulmonary embolism, major bleeding with prophylaxis, and iatrogenic bleeding from curative anticoagulation by multiplying the mean rate by its case-fatality rate. Fatal event rates were evaluated for 10,000 total hip or knee replacements and for 10,000 hip fractures. RESULTS: For 10,000 patients undergoing total hip or knee replacement, five fatal pulmonary embolisms and two fatal bleedings are expected, despite recommended extension of thromboprophylaxis. Curative anticoagulation of asymptomatic venous thrombosis would add nine fatal bleedings, 8/9 related to distal thrombosis care. For 10,000 patients undergoing hip fracture surgery, six fatal pulmonary embolisms and 23 fatal bleedings are expected. Curative anticoagulation of asymptomatic venous thrombosis would add 16 fatal bleedings, 14/16 related to distal thrombosis care. CONCLUSION: Curative anticoagulation of asymptomatic distal deep vein thromboses, leads to more fatal bleeding compared to avoidable fatal pulmonary embolism. These findings strengthen recommendations against routine ultrasound screening for asymptomatic distal deep vein thrombosis.
Subject(s)
Anticoagulants/therapeutic use , Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Heparin, Low-Molecular-Weight/therapeutic use , Postoperative Complications/prevention & control , Postoperative Hemorrhage/chemically induced , Premedication , Pulmonary Embolism/prevention & control , Venous Thrombosis/drug therapy , Aged , Anticoagulants/adverse effects , Asymptomatic Diseases , Female , Heparin, Low-Molecular-Weight/adverse effects , Hip Fractures/complications , Hip Fractures/surgery , Humans , Male , Middle Aged , Postoperative Hemorrhage/mortality , Postoperative Hemorrhage/prevention & control , Premedication/adverse effects , Pulmonary Embolism/mortality , Risk Assessment , Ultrasonography , Venous Thrombosis/diagnostic imagingABSTRACT
BACKGROUND: Recombinant activated factor VII (rFVIIa) is indicated in bleeding patients when a life-threatening haemorrhage occurs. Prothrombin complex concentrates (PCCs) are also used for this indication in several countries, without any evidence-based rationale. Our objective was to compare the efficacy and safety of PCC and rFVIIa in a model of bleeding and thrombosis in haemodiluted rabbits. METHODS: Forty-eight rabbits were randomly allocated into four groups: a control group and three treatment groups, in which animals were haemodiluted with hydroxyethyl starch 130/0.4 then administered either placebo, 160 µg kg(-1) rFVIIa, or 25 IU FIX kg(-1) PCC. The primary endpoint was hepatosplenic (HS) blood loss. Secondary endpoints were: (i) ear immersion bleeding time (IBT); (ii) thrombosis risk assessed by cyclic flow reductions (CFRs) of the carotid artery; and (iii) activated partial thromboplastin time (aPTT), and progress of thrombin activity. RESULTS: Haemodilution increased HS blood loss by 80% from 8 g (5-16) (control group) to 14 g (8-45) (placebo group) (P<0.01). HS blood loss was not different in animals receiving either rFVIIa [10 g (7-22)] or PCC [15 g (4-33)] (P<0.05) compared with the placebo group. Ear IBT was reduced with both rFVIIa and PCC. CFRs disappeared after haemodilution and were not restored with any treatment. Although PCC nearly doubled the total amount of thrombin generated, no significant change in the total amount of thrombin was seen in animals treated with rFVIIa. CONCLUSIONS: Neither rVIIa nor PCC reduced HS blood loss, whereas they both controlled the bleeding time, without increasing the thrombosis risk.
Subject(s)
Blood Coagulation Factors/therapeutic use , Coagulants/pharmacology , Factor VIIa/pharmacology , Hemorrhage/drug therapy , Thrombosis/drug therapy , Animals , Bleeding Time , Disease Models, Animal , Hemodilution , Hydroxyethyl Starch Derivatives/administration & dosage , Male , Partial Thromboplastin Time , Prothrombin Time , Rabbits , Recombinant Proteins/pharmacology , Treatment OutcomeABSTRACT
Direct oral anticoagulants (DOAs), inhibitors of factor IIa or Xa, are expected to replace vitamin K antagonists in most of their indications. It is likely that patients on long-term treatment with DOAs will be exposed to elective or emergency surgery or invasive procedures. Due to the present lack of experience in such conditions, we cannot make recommendations, but only propose perioperative management for optimal safety as regards the risk of bleeding and thrombosis. DOAs may increase surgical bleeding, they have no validated antagonists, they cannot be monitored by simple, standardised laboratory assays, and their pharmacokinetics vary significantly from patient to patient. Although DOAs differ in many respects, the proposals in the perioperative setting need not be specific to each. For procedures with low risk of haemorrhage, a therapeutic window of 48 h (last administration 24h before surgery, restart 24h after) is proposed. For procedures with medium or high haemorrhagic risk, we suggest stopping DOAs 5 days before surgery to ensure complete elimination of the drug in all patients. The treatment should be resumed only when the risk of bleeding has been controlled. In patients with a high risk of thrombosis (e.g. those in atrial fibrillation with an antecedent of stroke), bridging with heparin (low molecular weight, or unfractionated if the former is contraindicated) is proposed. In emergency, the procedure should be postponed for as long as possible (minimum 1-2 half-lives) and non-specific anti-haemorrhagic agents, such as recombinant human activated factor VIIa, or prothrombin concentrates, should not be given for prophylactic reversal, due to their uncertain benefit-risk.
Subject(s)
Anticoagulants/therapeutic use , Factor Xa Inhibitors , Surgical Procedures, Operative , Thrombin/antagonists & inhibitors , Administration, Oral , Anticoagulants/antagonists & inhibitors , Hemorrhage/epidemiology , Hemorrhage/etiology , Humans , Risk , Thrombosis/epidemiology , Thrombosis/etiologyABSTRACT
The anticoagulant market has been very active recently with the development of new compounds including injectable anti-Xa such as fondaparinux, already available, and idraparinux, already replaced by its new biotynilateed form, and new oral drugs which can be divided into anti-IIa with dabigatran already available, and anti-Xa, such as the recently marketed rivaroxaban and apixaban still in the development stage. Others are coming forward. The competition is strong and the place for each drug remains to be determined. This review discusses these new anticoagulants in terms of efficacy and tolerance based on data in the literature. These recent reports mainly concern prophylaxis for orthopedic surgery but also consider treatment of deep venous thrombosis. The results of studies in heart patients have raised much curiosity since they will be determinant in the future use of innovating compounds, which could replace current oral anticoagulants. This will be upcoming but not yet for tomorrow.
Subject(s)
Anticoagulants/therapeutic use , Antithrombins/therapeutic use , Factor Xa Inhibitors , Fondaparinux , Humans , Morpholines/therapeutic use , Oligosaccharides/therapeutic use , Polysaccharides/therapeutic use , Rivaroxaban , Thiophenes/therapeutic useABSTRACT
BACKGROUND: In view of recent substantial changes in the management of orthopedic surgery patients, a study was performed in order to update data on the epidemiology of venous thromboembolism (VTE) in patients undergoing lower limb arthroplasty according to contemporary practise. METHODS: We performed a prospective observational study of a cohort of consecutive patients hospitalized for total hip or knee replacement in June 2003. The primary study outcome was the incidence of symptomatic VTE at 3 months. All events were adjudicated by an independent critical event committee. RESULTS: Data from 1080 patients (mean age 68.0 years) were available; 63.2% were undergoing total hip replacement and 36.8% total knee replacement. Pharmacological thromboprophylaxis was administered for a mean time of 36 days. Injectable antithrombotics were used in more than 99% of patients, irrespective of the type of surgery. The incidence of the primary study outcome was 1.8% (20 events; 95% CI: 1.0-2.6%). The incidences were 1.3% and 2.8% in hip and knee surgery patients, respectively. There were two pulmonary embolisms, both in knee surgery patients; neither was fatal. Thirty-five per cent of VTEs occurred after hospital discharge. An age of at least 75 years and the absence of ambulation before hospital discharge were the only significant (P < 0.05) predictors of VTE. The rate of clinically significant bleeding was 1.0% and the rate of death was 0.9%. CONCLUSIONS: The incidence of symptomatic VTE after lower limb arthroplasty is low, even if there is still a need to improve thromboprophylaxis, notably in patients undergoing knee arthroplasty.
Subject(s)
Arthroplasty, Replacement, Hip/adverse effects , Arthroplasty, Replacement, Knee/adverse effects , Pulmonary Embolism/epidemiology , Venous Thromboembolism/epidemiology , Age Factors , Aged , Arthroplasty, Replacement, Hip/statistics & numerical data , Arthroplasty, Replacement, Knee/statistics & numerical data , Female , Fibrinolytic Agents/adverse effects , Fibrinolytic Agents/therapeutic use , France/epidemiology , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , Incidence , Male , Middle Aged , Population Surveillance , Prospective Studies , Pulmonary Embolism/etiology , Pulmonary Embolism/physiopathology , Pulmonary Embolism/prevention & control , Risk Factors , Time Factors , Treatment Outcome , Venous Thromboembolism/etiology , Venous Thromboembolism/physiopathology , Venous Thromboembolism/prevention & control , WalkingABSTRACT
BACKGROUND: Recombinant activated factor VII (rFVIIa) is increasingly used to secure hemostasis in hemorrhagic situations in trauma and surgical patients. Hypothermia is often observed in these clinical settings. OBJECTIVE: To study the efficacy and safety of rFVIIa in hypothermia in a rabbit model of bleeding and thrombosis. METHODS: Sixty-nine rabbits were anesthetized, ventilated and monitored for blood pressure, temperature and carotid flow. The Folts model was used: a stenosis (75%) and an injury were carried out on the carotid artery, inducing thrombosis. Blood flow decreased as thrombus size increased until the pressure gradient was such that the thrombus was released and local arterial blood flow was suddenly restored. This is known as a cyclic flow reduction (CFR). After counting baseline CFRs during a 20-min period (P1), rabbits were randomized blindly to one of four groups: normothermic (NT) placebo or rFVIIa (150 microg kg(-1)), hypothermic (HT) (34 degrees C) placebo or rFVIIa. Then CFRs were recorded over a second period (P2). At the end of the experiment, a hepato-splenic section was performed and the amount of blood loss was recorded. After each period, the following were measured: ear immersion bleeding time (BT), hemoglobin, platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT) and fibrinogen. RESULTS: Hypothermia increased BT and blood loss. These effects were reversed by rFVIIa. In NT rabbits, rFVIIa shortened BT but did not reduce blood loss. rFVIIa-treated rabbits bled similarly regardless of temperature. The incidence of CFRs was higher in treated than placebo animals regardless of temperature. rFVIIa decreased PT and aPTT without modifying platelet count or fibrinogen level. CONCLUSION: Hemostatic efficacy of rFVIIa was maintained in hypothermia. However, the number of CFRs was higher in the rFVIIa-treated group than in the placebo groups, whether for NT or HT rabbits.
Subject(s)
Factor VII/therapeutic use , Hemorrhage/drug therapy , Hypothermia , Thrombosis/chemically induced , Animals , Disease Models, Animal , Factor VIIa , Hemorrhage/complications , Hemostasis , Rabbits , Recombinant Proteins/therapeutic use , Regional Blood Flow , Single-Blind MethodABSTRACT
We report 13 cases of coronary stent patients, undergoing a non cardiac surgery. Despite an heterogenous perioperative management of antiplatelet agents, none of these patients developed any significant complications. Recently, several case reports of postoperative drug eluting stent thrombosis have been reported. However, the actual incidence of this dramatic event is not known. This confirms the need to perform prospective studies or registries of patients with coronary stents undergoing non cardiac surgery, in order to propose evidence-based recommendations on perioperative antiplatelet management in such patients.
Subject(s)
Anesthesia, General , Platelet Aggregation Inhibitors/therapeutic use , Postoperative Complications/prevention & control , Stents/adverse effects , Surgical Procedures, Operative , Thrombophilia/etiology , Thrombosis/prevention & control , Aged , Aged, 80 and over , Coronary Restenosis/prevention & control , Coronary Stenosis/surgery , Drug Implants , Female , France , Hematoma/etiology , Humans , Incidence , Male , Middle Aged , Paclitaxel/administration & dosage , Paclitaxel/therapeutic use , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Prospective Studies , Registries , Sirolimus/administration & dosage , Sirolimus/therapeutic useABSTRACT
OBJECTIVE: This study was undertaken to quantify the use of chronic medication and herbal remedies in the presurgical population. STUDY DESIGN: Prospective multicenter survey. PATIENTS AND METHODS: Adult patients presenting for anaesthesia were directly asked if they were currently using chronic medication or herbal remedies. RESULTS: Among 1057 patients (age 54+/-17 yrs, woman 54%, ASA 2 [1-4], 74%) were taking one or more chronic medication. The most commonly used treatments were, in descending order angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers (15%), beta blockers (11%) and platelet inhibitors (10%). Also, 9% were taking one or more of the following herbal remedies known to interact with the perioperative period: valeriane, ginseng, ginkgo, St John's wort, echinacea and ephedra. Women and patients aged 40-70 yr were most likely to be taking a herbal product (p<0.001 and p<0.01 respectively). CONCLUSION: Chronic medication and herbal remedies are common in patients presenting for anaesthesia. Because of the potential interactions between anaesthetic drugs or techniques and such medication it is important for anaesthetists to be aware of their use.